TELA earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -0.93. Updated 2026-07-23.
TELA Bio (TELA) Research Hub
TELA Bio (TELA) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 0.97 USD (+6.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.93, market cap 0.03B. This hub links to the full technical, earnings and options research available for TELA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.97 USD (+6.44%) |
| 52-week range | 0.6035 USD – 0.9945 USD |
| Trend regime | Range |
| 14-day RSI | 58.5 (Bullish) |
| Trailing P/E | -0.93 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for TELA
Covered Call on TELA: how it works, illustrative setup around the real 0.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TELA: how it works, illustrative setup around the real 0.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TELA: how it works, illustrative setup around the real 0.97 USD price, max profit/loss, breakeven and when to use it. Educational.
TELA technical analysis: range, last 0.97 USD, RSI 58.5, 52w range 0.6035 USD–0.9945 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TELA in?
TELA Bio (TELA) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is TELA in an uptrend or downtrend?
As of 2026-09-11, TELA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TELA's trailing P/E ratio?
TELA's trailing P/E is -0.93, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does TELA next report earnings?
TELA is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.17 USD.